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Abstract
Background: The maturation inhibitor bevirimat (BVM) potently inhibits human immunodeficiency virus type 1 (HIV-1) 
replication by blocking capsid-spacer peptide 1 (CA-SP1) cleavage. Recent clinical trials demonstrated that a significant 
proportion of HIV-1-infected patients do not respond to BVM. A patient's failure to respond correlated with baseline 
polymorphisms at SP1 residues 6-8.
Results: In this study, we demonstrate that varying levels of BVM resistance are associated with point mutations at 
these residues. BVM susceptibility was maintained by SP1-Q6A, -Q6H and -T8A mutations. However, an SP1-V7A 
mutation conferred high-level BVM resistance, and SP1-V7M and T8Δ mutations conferred intermediate levels of BVM 
resistance.
Conclusions: Future exploitation of the CA-SP1 cleavage site as an antiretroviral drug target will need to overcome the 
baseline variability in the SP1 region of Gag.
Background
Human immunodeficiency virus type 1 (HIV-1) infectiv-
ity is dependent on virion maturation, a morphological
rearrangement of the viral core that occurs concomitant
with virus particle release [1,2]. HIV-1 maturation is trig-
gered by cleavage of the Gag polyprotein, catalyzed by the
viral protease (PR), into the matrix (MA), capsid (CA),
spacer peptide 1 (SP1), nucleocapsid (NC), spacer pep-
tide (SP2) and p6 constituents. Gag cleavage occurs as a
sequential cascade of steps that is kinetically controlled
by the differential rate of processing at each of the five
cleavage sites in Gag [3-9]. First, Gag is cleaved into two
fragments, MA-CA-SP1 and NC-SP2-p6. Next, the MA
and p6 domains are released, and finally the CA and NC
domains are liberated from the remaining CA-SP1 and
NC-SP2 processing intermediates. Morphological rear-
rangement of the viral core is triggered by the release of
the mature CA domain, which reassembles into a hexa-
meric lattice to form a condensed conical core.
The small molecule 3-O-(3',3'-dimethylsuccinyl)-betu-
linic acid (DSB), also known as PA-457, MPC-4326, or
bevirimat (BVM), potently inhibits HIV-1 replication by
inhibiting a late step in the proteolytic processing cascade
of Gag by specifically blocking the cleavage of SP1 from
the C-terminus of CA [10-12]. Inhibiting CA-SP1 cleav-
age results in the formation of aberrant, non-infectious
particles that fail to undergo proper maturation [9,10].
The novel mechanism of action of BVM led to its desig-
nation as the first in a new class of antiretroviral drugs
known as maturation inhibitors [1,13,14].
The potent in vitro activity of BVM [10], together with
promising pharmacological and safety profiles in animal
models and phase I clinical trials [15-18], led to clinical
testing of BVM efficacy in HIV-1-infected patients. Initial
phase II clinical trials reported statistically significant,
dose-dependent viral load reductions in HIV-1-infected
patients [19]. However, further studies showed that up to
50% of patients receiving BVM did not exhibit significant
viral load reductions [20]. Optimal BVM plasma concen-
trations were observed in many of the non-responder
patients, implying that virological parameters could be
responsible for part of the observed variable clinical out-
come [20]. Population genotyping of patient isolates dem-
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Page 2 of 8onstrated that the BVM-resistance mutations identified
in in vitro selection studies were not present in the non-
responding cohort [21]. The in vitro selected BVM-resis-
tance mutations map to three highly conserved residues
at the extreme C-terminus of CA (CA-H226Y, L231M
and L231F) and the first and third residues of SP1 (SP1-
A1V, A3V and A3T) [10,11,22]. Instead, the presence of
baseline polymorphisms at SP1 residues 6-8 in the rela-
tively non-conserved C-terminal portion of SP1 corre-
lated with patients' failure to respond [20]. Patients
infected with isolates encoding the clade B consensus
amino acid sequence glutamine-valine-threonine (QVT)
at these positions were significantly more likely to
respond to BVM treatment than were patients infected
with virus encoding polymorphisms at these positions
[20].
A high-throughput in vitro phenotypic infectivity assay
has been used to evaluate the correlation between a panel
of naturally occurring Gag polymorphisms at SP1 resi-
dues 6-8 (SP1/6-8) and BVM susceptibility [23]. Specific
polymorphisms at SP1 residues 7 and 8 (SP1-V7A, -V7M,
-T8Δ and -T8N) were shown to be sufficient to confer
decreased BVM susceptibility, while other mutations at
SP1 residues 6 and 8 (SP1-Q6A, -Q6H and -T8A)
retained sensitivity [23]. BVM susceptibility was reported
as a fold change in IC50 value; the impact of these muta-
tions on CA-SP1 processing or replication fitness was not
reported.
Results and Discussion
Effect of SP1 mutations on CA-SP1 processing
To extend our understanding of the relationship between
Gag polymorphisms at SP1/6-8 and BVM susceptibility,
we employed a quantitative biochemical CA-SP1 process-
ing assay that we have previously used to analyze in vitro-
selected BVM-resistance mutations [22,24]. Point muta-
tions at SP1/6-8 were introduced into the infectious HIV-
1 molecular clone pNL4-3 [25] to generate pNL4-3 SP1-
Q6A, -Q6H, -V7A, -V7 M, -T8A and -T8Δ (Fig. 1A). This
panel includes both alanine-scanning mutations across
the residues of interest and several observed Gag poly-
morphisms (SP1-Q6H, -V7A, -V7 M, -T8A, and -T8Δ)
[23,26]. WT pNL4-3, which contains the QVT motif at
SP1/6-8, was used as a BVM-susceptible virus and the
previously characterized SP1-A1V mutant served as a
prototypical BVM-resistant virus [10,16,22,24]. The CA-
SP1 processing assay was performed as previously
described [22,24,27]. Briefly, HeLa cells transfected with
WT or mutant pNL4-3 molecular clones were cultured
either with no drug or with 1 μg/ml BVM. The cells were
metabolically labeled with [35S]Met/Cys, and cell- and
virion-associated proteins were immunoprecipitated
with HIV-Ig. CA-SP1 cleavage was detected (Fig. 1B) and
quantified as the percentage of CA-SP1 relative to total
CA-SP1 plus CA (Fig. 1C). Consistent with our previous
results, treatment of WT-transfected cells with BVM
resulted in a marked accumulation of CA-SP1 in both cell
and virion fractions. Similar levels of CA-SP1 were
observed in the SP1-Q6A, -Q6H and -T8A BVM-treated
samples. In contrast, CA-SP1 processing in SP1-V7A
BVM-treated samples was similar to that seen in
untreated WT or SP1-A1V samples. Interestingly, inter-
mediate levels of CA-SP1 processing were observed in
SP1-V7M and -T8Δ virions produced from BVM-treated
cells. The result with SP1-T8Δ is consistent with previous
analysis of this mutant [28]. The biochemical data
obtained were also used to estimate virus release effi-
ciency for each of the SP1 mutant derivatives in the
absence and presence of BVM relative to untreated WT.
Virus release efficiency was not significantly affected,
with the exception of the SP1-V7A mutant cultured in the
absence of drug, where a 3-fold reduction in virus release
efficiency was observed (data not shown).
Effect of SP1 mutations on sensitivity to BVM in a single-
cycle infectivity assay
We next sought to examine the effect of the SP1/6-8
mutations on virus infectivity using a single-cycle infec-
tivity assay in the TZM-bl indicator cell line [29,30]. Viri-
ons produced from transfected HeLa cells cultured either
without drug or with 1 μg/ml BVM were used to infect
TZM-bl cells and luciferase activity was measured 48
hours postinfection (Fig. 2). The SP1/6-8 mutations did
not significantly impact virus infectivity when particles
were generated in the absence of BVM. However, virus
infectivity was clearly inhibited when the WT, SP1-Q6A,
-Q6H and -T8A viruses were generated in the presence of
BVM. In contrast, BVM treatment did not reduce the
ability of SP1-A1V or -V7A viruses to infect TZM-bl
cells. Infectivity of viruses harboring the SP1-V7M and -
T8Δ mutations was only moderately inhibited when pro-
duced in the presence of BVM.
Effect of SP1 mutations on sensitivity to BVM in the context 
of a spreading infection
The biochemical and single-cycle infectivity data pre-
sented above suggest that the SP1/6-8 mutations confer
varying levels of BVM resistance without compromising
virus infectivity. To confirm this result and determine the
effects of these mutations on virus replication capacity,
we evaluated virus replication kinetics in the Jurkat T cell
line. Each construct was transfected into the Jurkat T-cell
line, and the cells were cultured either without BVM or in
the presence of a suboptimal (50 ng/ml) or inhibitory (1
μg/ml) drug concentration (Fig. 3). Virus replication was
monitored by RT activity. The maintenance of existing
and/or acquisition of additional mutations was deter-
mined by extracting genomic DNA from cells at the peak
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ing regions and DNA sequencing [22,24,27] (Fig. 3). WT
virus was fully inhibited at 1 μg/ml BVM but developed
BVM resistance after 47 days in the presence of 50 ng/ml
BVM by acquisition of an SP1-V7A mutation. The SP1-
V7A substitution has not been observed in previous in
vitro BVM-resistance selection studies [10,11,22,24]. In
agreement with our previous studies, the SP1-A1V
mutant was fully resistant to BVM as it replicated with
WT kinetics independent of BVM concentration and did
not acquire additional mutations. The SP1/6-8 mutations
were maintained in all cultures in which detectable virus
replication occurred. In the absence of BVM, the mutant
viruses replicated with essentially WT kinetics and did
not acquire additional amino acid substitutions, demon-
strating that no significant fitness cost was associated
with the SP1/6-8 mutations in the Jurkat cell system. The
SP1-V7A mutation exhibited resistance to BVM as its
replication was only moderately delayed with increasing
BVM concentration and it replicated without acquiring
additional mutations. At the 50 ng/ml BVM concentra-
tion, the SP1-V7M virus was capable of replicating, albeit
with a significant delay, without acquiring additional
amino acid substitutions. However, at the 1 μg/ml con-
centration, detectable replication was even further
delayed and was accompanied by the acquisition of an
SP1-A1T substitution (Fig. 3). Although the SP1-A1T
change has not previously been reported in association
with BVM resistance [10,11,22,24], it maps to the same
residue as the robust SP1-A1V BVM-resistance mutation.
In a repeat experiment, the same pattern of replication
and mutation acquisition was observed for the V7M
Figure 1 Mutagenesis at SP1 residues 6-8 results in varying degrees of CA-SP1 processing in the presence of BVM. (A) Mutagenesis of SP1 
residues 6-8. HIV-1 Gag is represented at the top. The MA, CA, NC and p6 domains and the SP1 and SP2 spacer peptides are indicated. The alignment 
shows the pNL4-3 wild type (WT) amino acid sequence at the CA-SP1 junction in Gag and the panel of SP1 mutant derivatives examined in this study. 
The residues to which BVM resistance was previously mapped in vitro are shaded in grey. (B and C) Quantitative CA-SP1 processing assay. HeLa cells 
were transfected with WT pNL4-3 and the panel of SP1 mutant derivatives and cultured either without BVM or in 1 μg/ml BVM. Cells were metaboli-
cally labeled for 2 h with [35S]Met/Cys, and released virions were pelleted by ultracentrifugation. Cell and virus lysates were immunoprecipitated with 
HIV-Ig, and processing of CA-SP1 to CA was analyzed by SDS-PAGE and fluorography (B) and by phosphorimager analysis to quantify the percentage 
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Page 4 of 8mutant, except that at 1 μg/ml BVM a CA-V230I substi-
tution and the previously characterized SP1-A3V muta-
tion were detected when virus replication emerged after
29 days in culture (data not shown). The CA-V230I sub-
stitution has previously been reported to be acquired in
the context of a CA-L231 MBVM-resistance mutation
combined with a mutant PR when propagated in the
presence of BVM [24]. Interestingly, the CA-V230I sub-
stitution occurs frequently in HIV-1 isolates [26,31,32]
and therefore could represent an additional Gag poly-
Figure 2 Residue 6-8 mutations result in varying levels of resistance to BVM. (A) Virus stocks produced from HeLa cells either in the absence of 
BVM or in the presence of 1 μg/ml BVM were used to infect the TZM-bl indicator cell line. Infectivity was measured 48 h postinfection by determining 
levels of luciferase activity. Relative infectivity was calculated by normalization of the untreated WT virus at the 12.5 μl viral input to 100%. Paired t tests 
were performed to evaluate differences between means. Statistically significant differences between pairs of means are indicated (*** P = 0.0001, ** 
P = 0.001, * = 0.01). (B) Virus inputs were verified by confirming that virus stocks contained comparable RT activities. All data shown are means and 
standard deviations from three independent experiments, performed in duplicate.
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Figure 3 Replication kinetics of viruses containing mutations in SP1 residues 6-8. Jurkat T cells were transfected with WT pNL4-3 and the panel 
of SP1 mutant derivatives and cultured either without BVM or in 50 ng/ml or 1 μg/ml BVM. Cells were split every 2 days, and supernatants were re-
served at each time point for RT analysis. All originally introduced mutations were maintained. The grey boxes indicate those cultures in which an 
additional mutation is acquired; both the introduced and the acquired mutations are indicated. The results shown are representative of at least 2 in-
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Page 6 of 8morphism associated with BVM resistance. Replication
of SP1-T8Δ was significantly delayed at the 50 ng/ml
BVM concentration and was only detected upon acquisi-
tion of the SP1-A1V BVM-resistance mutation (Fig. 3).
No detectable replication was observed for the SP1-T8Δ
virus at 1 μg/ml BVM for up to 53 days in culture. How-
ever, in a repeat experiment, replication emerged after 68
days in culture and was accompanied by acquisition of
the SP1-A3V mutation (data not shown). No replication
was detectable for the SP1-Q6A and -Q6H mutants in the
presence of either 50 ng/ml or 1 μg/ml BVM. The SP1-
T8A virus did not replicate at 50 ng/ml BVM; however,
replication of this mutant was detected at 1 μg/ml BVM
at day 45 posttransfection and was accompanied by
acquisition of the SP1-A3V mutation (Fig. 3).
Conclusions
The data presented here demonstrate that point muta-
tions corresponding to commonly observed polymor-
phisms at SP1 residues 6-8 in HIV-1 clinical isolates
confer varying degrees of susceptibility to BVM in the
NL4-3 background. The SP1-Q6A, Q6H, and T8A
mutants retained complete sensitivity to BVM. Mutations
SP1-V7M and T8Δ exhibited an intermediate level of
BVM susceptibility. The SP1-V7M mutant appeared less
susceptible to BVM than did SP1-T8Δ; SP1-V7M BVM-
treated virions accumulated less unprocessed CA-SP1
and the SP1-V7M virus replicated without acquisition of
additional mutations at 50 ng/ml BVM, whereas robust
SP1-T8Δ replication required acquisition of a previously
characterized BVM-resistance mutation. The SP1-V7A
mutant displayed full resistance to BVM in terms of CA-
SP1 processing, single-cycle infectivity, and virus replica-
tion assays, and its resistance was comparable to that of
the robust and frequently observed BVM-resistance
mutant SP1-A1V.
The observed variability in BVM susceptibility con-
ferred by different mutations at SP1 residues T8 and V7 is
likely due to differential effects on the putative BVM
binding pocket at the CA-SP1 junction of Gag. For exam-
ple, deletion of residue 8 is a more substantial change
than a T-to-A substitution and could therefore be pre-
dicted to have a greater effect on BVM's ability to bind
Gag and exert its antiviral affect. Hence the T8Δ mutant
exhibits intermediate resistance to BVM while T8A
retains BVM susceptibility. Although binding of BVM to
the CA-SP1 junction has previously been suggested by
biochemical studies that examined other BVM-resistant
mutants [33,34], the lack of high-resolution structural
information on this region of Gag hinders further eluci-
dation at this time.
The data obtained in this study are in close agreement
with the previously reported high-throughput pheno-
typic assay used to evaluate the association between Gag
polymorphisms at SP1/6-8 and BVM susceptibility [23].
However, we extend the prior findings by evaluating the
effects of SP1/6-8 mutations on CA-SP1 processing in the
presence and absence of BVM, measuring the effects of
these mutations on viral replication capacity, and per-
forming BVM selections analyses with these mutants. In
conclusion, baseline polymorphisms in the non-con-
served C-terminal portion of SP1 represent a consider-
able challenge to the clinical development of BVM. In
particular, the SP1-V7A polymorphism constitutes a sig-
nificant obstacle as it displayed robust BVM-resistance in
in vitro assays and has been shown to occur at high fre-
quency in some HIV-1 subtypes [23]. Future exploitation
of the CA-SP1 cleavage site as a molecular target for anti-
retroviral drug development will need to account for the
baseline amino acid variability in this region of Gag.
Methods
BVM and cell culture
BVM was prepared as described previously [35] and used
at the concentrations indicated. HeLa cells were main-
tained in Dulbecco Modified Eagle Medium (DMEM)
supplemented with 5% (vol/vol) fetal bovine serum (FBS).
TZM-bl indicator cells [obtained through the NIH AIDS
Research and Reference Reagent Program, Division of
AIDS, NIAID; [[29,30]] were maintained in DMEM sup-
plemented with 10% (vol/vol) FBS. The Jurkat T-cell line
was maintained in RPMI-1640 supplemented with 10%
(vol/vol) FBS. All media were supplemented with L-glu-
tamine (2 mM), penicillin and streptomycin.
Generation of SP1 mutants and transfections
Point mutations at SP1 residues 6-8 (SP1/6-8) were intro-
duced into the infectious HIV-1 molecular clone pNL4-3
[25] by using site-directed mutagenesis to generate
pNL4-3 SP1-Q6A, Q6H, V7A, V7 M, T8A and T8Δ (Fig.
1A). Plasmid DNA was purified with the plasmid purifi-
cation maxiprep kit (QIAGEN), adjusted to 1 μg/μl and
the identities of all plasmids were confirmed by DNA
sequencing. HeLa cells were transfected with Lipo-
fectamine 2000 (Invitrogen) according to the manufac-
turer's instructions. Jurkat T cells were transfected by
using DEAE-dextran [36].
Radioimmunoprecipitation analysis
Methods used for metabolic labeling of HeLa cells, prepa-
ration of cell and virus lysates, and immunoprecipitation
have been previously described in detail [22,27,37].
Briefly, media and solutions containing BVM at the indi-
cated concentrations were prepared immediately before
use and mixed by vortexing. BVM was maintained
throughout the transfection and radioimmunoprecipita-
tion procedures. HeLa cells were transfected with wild-
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Transfected HeLa cells were starved in Cys/Met-free
medium for 30 min and then metabolically radiolabeled
for 2 h with [35S]Cys/Met Pro-mix (Amersham). Virions
were pelleted by ultracentrifugation. Cell and virus
lysates were immunoprecipitated with pooled immuno-
globulin from HIV-1-infected patients (HIV-Ig) obtained
through the NIH AIDS Research and Reference Reagent
Program, Division of AIDS, NIAID. The radioimmuno-
precipitated proteins were separated by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
and exposed to X-ray film and a phosphorimager plate
(Fuji) and the bands were quantified by using Quantity
One software (Bio-Rad).
Single-cycle infectivity assay
Virus stocks of were produced by transfecting HeLa cells
with WT and SP1 mutant pNL4-3 derivatives and then
cultured either without BVM or with 1 μg/ml BVM.
Twenty-four hours posttransfection, the cells were
washed twice and fresh medium containing either no
BVM or 1 μg/ml BVM was added. Following a 4-hour
incubation, virus-containing supernatant was collected,
filtered and used to infect TZM-bl cells. Infections were
carried out for 2 hours in the presence of 10 μg/ml
DEAE-dextran. The cells were then washed, cultured
without BVM, and luciferase activity measured 48 hours
postinfection using the luciferase assay system (Pro-
mega). Reverse transcriptase (RT) activities in the virus
stocks were measured as previously described [27].
Replication kinetics
Jurkat T cells were transfected with pNL4-3 WT and SP1
mutant derivatives. BVM was added at the time of trans-
fection at the indicated concentrations and was main-
tained throughout the course of the experiment. The
Jurkat cells were split every two days, supernatant col-
lected at each time point and viral replication monitored
by RT activity as previously described [27]. Cell pellets
and virus supernatants were harvested on the days of
peak RT activity. To verify that the SP1 mutations were
maintained and to investigate acquisition of additional
mutations, genomic DNA was extracted from cells on the
day of peak RT activity using a whole-blood DNA extrac-
tion kit (QIAGEN). The entire Gag-PR coding region was
then amplified by PCR by using the forward and reverse
primers NL516F (5'-TGC CCG TCT GTT GTG TGA
CTC-3') and NL2897R (5'-AAA ATA TGC ATC GCC
CAC AT-3') respectively. The resultant 2.3 kb PCR prod-
uct was purified by using the QIAquick PCR purification
kit (QIAGEN) and sequenced using the primers NL1410F
(5'-GGA AGC TGC AGA ATG GGA TA-3'), NL1754F
(5'-TGG TCC AAA ATG CGA ACC-3') and NL2135F (5'-
TTC AGA GCA GAC CAG AGC CAA-3') [22,24].
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